Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 16/20 | 0.65 |
| ▸ | CYP17A1 | P05093 | 13/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Seviteronel SCHEMBL23299702 | 0.88 | CYP3A4 (0.69) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| Seviteronel SCHEMBL30596789 | 0.88 | CYP3A4 (0.69) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| Seviteronel SCHEMBL4561168 | 0.88 | CYP3A4 (0.69) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| Seviteronel SCHEMBL20459170 | 0.88 | CYP3A4 (0.69) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| Seviteronel SCHEMBL29364397 | 0.88 | CYP3A4 (0.69) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL8745699 | 0.87 | CYP3A4 (0.49) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL5020315 | 0.81 | CYP3A4 (0.68) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL4027994 | 0.81 | CYP3A4 (0.64) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL4026634 | 0.81 | CYP3A4 (0.64) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL4560810 | 0.80 | CYP3A4 (0.67) | CYP3A4CYP17A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3483147-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Innocrin Pharmaceuticals, Inc. (US) | 2019-05-15 | — | — | EP | claimed |
| US-20180221364-A1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS, INC. | 2018-08-09 | — | — | US | claimed |
| US-20170143694-A1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS, INC. | 2017-05-25 | — | — | US | claimed |
| US-20140121248-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2014-05-01 | — | — | US | claimed |
| US-8623892-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-01-07 | — | — | US | claimed |
| US-20130184309-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | US | claimed |
| US-8389543-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2013-03-05 | — | — | US | claimed |
| US-20120129886-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | claimed |
| US-12357615-B2 | Compositions for the treatment of brain tumors | KEMBI THERAPEUTICS PTY LTD (AU) | 2025-07-15 | — | — | US | disclosed |
| US-20220370415-A1 | COMPOSITIONS FOR THE TREATMENT OF BRAIN TUMORS | KEMBI THERAPEUTICS PTY LTD (AU) | 2022-11-24 | — | — | US | disclosed |
| WO-2019182743-A1 | COMPOSITIONS FOR THE TREATMENT OF BRAIN TUMORS | INNOCRIN PHARMACEUTICALS, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
| EP-3483147-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Innocrin Pharmaceuticals, Inc. (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-2638021-B1 | 1-(6,7-Bis(difluoromethoxy)naphthalen-2-yl)-2-methyl-1-(1H-1,2,3-triazol-4-yl)propan-1-ol as inhibitor of CYP17 for the treatment of androgen dependent diseases like prostate cancer | INNOCRIN PHARMACEUTICALS INC (US) | 2018-09-26 | — | — | EP | disclosed |
| US-20180221364-A1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20130184309-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-8389543-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389543-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120129886-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129886-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2012064943-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140121248-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CYP3A4 558/4885CYP17A1 649/4885CYP2C9 840/4885 |
| US-20180221364-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CYP3A4 558/4885CYP17A1 649/4885CYP2C9 840/4885 |
| US-20220370415-A1 | COMPOSITIONS FOR THE TREATMENT OF BRAIN TUMORS | NR3C2, NR3C1, CRH | CYP3A4 2554/4885CYP17A1 62/4885CYP2C9 4022/4885 |
| US-20130184309-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CYP3A4 558/4885CYP17A1 649/4885CYP2C9 840/4885 |
| US-20170143694-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CYP3A4 558/4885CYP17A1 649/4885CYP2C9 840/4885 |
| US-20120129886-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CYP3A4 558/4885CYP17A1 649/4885CYP2C9 840/4885 |
| US-12357615-B2 | Compositions for the treatment of brain tumors | NR3C2, NR3C1, CRH | CYP3A4 2554/4885CYP17A1 62/4885CYP2C9 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.